Nasdaq
$11.44▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $960.3MShares out 84.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
18- 9.16After-hours26.09.17 05:058-KKey event#●●●
Replimune Group, Inc.
Replimune Group received stockholder approval at its annual meeting on September 15, 2026, to amend its certificate of incorporation to increase the number of authorized shares of common stock from 150 million to 300 million. The certificate of amendment was filed with the Secretary of State of Delaware and became effective immediately on the same day.…more
$11.44+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.24After-hours26.08.25 08:484Ownership
Replimune Group, Inc.
Insider Philip Astley-Sparke of Replimune Group, Inc. reported a change in beneficial ownership of securities effective August 20, 2026. This filing was submitted via SEC Form 4 to disclose the insider's transaction.…more
$11.44+0.00%vs prev closeView filingShare - 8.19After-hours26.08.20 07:424Ownership
Replimune Group, Inc.
Emily Luisa Hill, an insider at Replimune Group, reported a change in beneficial ownership of company securities effective August 17, 2026. This filing serves as an official record of the insider's equity position change via Form 4.…more
$11.44+0.00%vs prev closeView filingShare
17 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.22 21:00#●●●#●●●
Replimune to Report Fiscal Q2 2027 Financial Results on October 28
Replimune announced it will host a conference call on October 28, 2026, to discuss its fiscal second quarter financial results and provide a corporate update. This is a routine earnings announcement and does not contain specific performance data.…more
$11.44+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1After-hours26.10.02 05:02
●●●●●●●● ●●●●● ●●●●●●
Replimune Group announced the commercial availability of TUDRIQEV in the United States for treating unresectable advanced cutaneous melanoma. The therapy is indicated for use in combination with nivolumab in adult patients who progressed on prior PD-1-blocking antibody regimens.…more
$11.44+0.00%vs prev closeShareBenzinga - 9.16After-hours26.09.17 05:11
●●●●●●●● ●●●●● ●●●●●●
Replimune shareholders have approved an amendment to increase the company's authorized common shares from 150 million to 300 million. This move enables potential future equity financing, which may lead to shareholder dilution.…more
$11.44+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report